TickerFacts.

Gilead Sciences, Inc. (GILD): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$5.80B
Year ended 2025-12-31
$6.07B
Trailing 12 months to 2026-06-30
+5.2%
3-year compound annual growth
+3.3%
5-year compound annual growth
$5.91B2007-12-31: $591.03M2008-12-31: $721.77M2009-12-31: $939.92M2010-12-31: $1.07B2011-12-31: $1.23B2012-12-31: $1.76B2018-12-31: $3.92B2019-12-31: $4.05B2020-12-31: $4.93B2021-12-31: $4.60B2022-12-31: $4.98B2023-12-31: $5.72B2024-12-31: $5.91B2025-12-31: $5.80B$5.80B
2007-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$5.80B-1.8%2026-02-24, From 2025-01-01
2024-12-31$5.91B+3.3%2026-02-24, From 2024-01-01
2023-12-31$5.72B+14.9%2026-02-24, From 2023-01-01
2022-12-31$4.98B+8.2%2025-02-28, From 2022-01-01
2021-12-31$4.60B-6.6%2024-02-23, From 2021-01-01
2020-12-31$4.93Bn/c2023-02-22, From 2020-01-01
2019-12-31$4.05B+3.4%2022-02-23, From 2019-01-01
2018-12-31$3.92Bn/a2021-02-25, From 2018-01-01
No annual figure between 2012-12-31 and 2018-12-31.
2012-12-31$1.76B+43.2%2013-02-27, From 2012-01-01
2011-12-31$1.23B+14.6%2013-02-27, From 2011-01-01
2010-12-31$1.07B+14.2%2013-02-27, From 2010-01-01
2009-12-31$939.92M+30.2%2012-02-23, From 2009-01-01
2008-12-31$721.77M+22.1%2011-02-28, From 2008-01-01
2007-12-31$591.03Mn/a2010-03-01, From 2007-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Gilead Sciences, Inc. (GILD)2025-12-31$5.80B-1.8%
Amgen Inc (AMGN)2025-12-31$7.27B+21.9%
Biogen Inc. (BIIB)2025-12-31$1.78B-10.2%
Neurocrine Biosciences Inc (NBIX)2025-12-31$1.02B+38.9%
Exelixis, Inc. (EXEL)2026-01-02$825.00M-9.4%
Qiagen N.V. (QGEN)2025-12-31$187.52M-3.1%
Moderna, Inc. (MRNA)2025-12-31$3.13B-31.1%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$81.49M+3.1%
Bio-Techne Corp (TECH)2026-06-30$94.77M-4.8%

Compare GILD, AMGN, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗